ALBERT BOURLA, DVM, PH.D.
As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose: breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health.
During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as the Pfizer’s Chief Operating Officer (COO) beginning in January 2018, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions.
Previously, from February 2016 to December 2017, Albert served as Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. In addition, he created the Patient and Health Impact Group, dedicated to developing solutions for increasing patient access, demonstrating the value of Pfizer’s medicines, and ensuring broader business model innovation.
From January 2014 to January 2016, Albert served as Group President of Pfizer’s Global Vaccines, Oncology, and Consumer Healthcare business, where he was instrumental in building a strong and competitive position in Oncology and expanding the Company’s leadership in Vaccines.
Albert was President and General Manager of Pfizer’s Established Products business from 2010-2013, leading the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio, (including legacy brands and generics.
He began his Pfizer career in 1993 in the Animal Health Division as Technical Director of Greece. He held positions of increasing responsibility within Animal Health across Europe, before moving to Pfizer’s New York Global Headquarters in 2001. From there, Albert went on to assume a succession of leadership roles within the Animal Health Division, including US Group Marketing Director (2001-2004), Vice President of Business Development and New Products Marketing (2004-2006), and Area President of Animal Health Europe, Africa and the Middle East (2006-2009). In 2009, he assumed additional responsibilities for the Asia and Pacific regions.
Albert is a Doctor of Veterinary Medicine and holds a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. In 2020, he was ranked as America’s top CEO in the Pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of The Partnership for New York City, a director on multiple boards – Pfizer, Inc., The Pfizer Foundation, PhRMA, and Catalyst – and a Trustee of the United States Council for International Business. In addition, Albert is a member of the Business Roundtable and the Business Council.